01—Abstract
Summary
Summary of the 8-K filed November 3, 2025. Cited figures are marked; the original filing is the authoritative source.
Medtronic plc announced on November 2, 2025, that its Executive Vice President, Enterprise Operations, Gregory L.
Smith, will retire from the company effective December 2, 2025. Mr. Smith's departure marks a leadership transition within the company's operations segment. Investors should note that his retirement triggers specific provisions regarding his outstanding equity compensation, as detailed in the company's filings.
02—Key points
Key Highlights
- Gregory L. Smith, EVP, Enterprise Operations, is retiring effective December 2, 2025.
- Mr. Smith is moving to a private equity-held organization.
- Upon retirement, Mr. Smith will receive retirement treatment for his outstanding equity compensation.
- This includes acceleration of unvested stock options.
- Restricted Stock Units (RSUs) and Performance Stock Units (PSUs) will continue vesting as per award agreements.
- Details on equity compensation treatment are available in the company's August 25, 2025 proxy statement and publicly filed award agreements.
03—Questions
Frequently Asked Questions
Who is leaving Medtronic and what is their role?
Gregory L. Smith, Executive Vice President of Enterprise Operations, is retiring from Medtronic.
When is Mr. Smith's departure effective?
His retirement is effective December 2, 2025.
What happens to Mr. Smith's equity awards upon his retirement?
Mr. Smith will be eligible for retirement treatment on his outstanding equity compensation. This involves the acceleration of unvested stock options and the continued vesting of RSUs and PSUs, consistent with the terms of the award agreements.
Where can I find more information about the equity compensation terms?
Details regarding the retirement treatment of equity compensation can be found in Medtronic's definitive proxy statement filed on August 25, 2025, and the associated equity award agreements filed with the SEC.
04—Continue